Northwest Biotherapeutics (OTCMKTS:NWBO) Shares Cross Below 200 Day Moving Average – Should You Sell?

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) shares crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.25 and traded as low as $0.2180. Northwest Biotherapeutics shares last traded at $0.2201, with a volume of 1,362,734 shares traded.

Northwest Biotherapeutics Stock Performance

The business has a 50 day moving average of $0.26 and a two-hundred day moving average of $0.25. The stock has a market capitalization of $363.72 million, a PE ratio of -0.01 and a beta of -0.81.

Northwest Biotherapeutics Company Profile

Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.

The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.